Navigation Links
Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
Date:11/13/2008

ATLANTA, Nov. 13 /PRNewswire/ -- CorMatrix Cardiovascular Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM(TM)) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that the company was awarded the 2008 Frost & Sullivan Healthcare Innovation Award in the treatment of cardiovascular disease.

The award recognizes CorMatrix's contribution to the cardiovascular market through its involvement in the research, development and marketing of its ECM Technology(TM) for pericardial closure and cardiac tissue repair.

"Frost & Sullivan acknowledges CorMatrix's dedication in the development of the unique ECM Technology(TM). Through this unique technology the company strives to meet the ever growing demand and continuous innovation that characterizes the cardiac device market," said Frost & Sullivan industry analyst Archana Swathy. "This exceptional product enhances the patient's recovery after surgery by facilitating efficient tissue repair."

The company's ECM Technology(TM) product acts as a scaffold into which the patient's own cells migrate and integrate, stimulating the body's innate wound-healing mechanisms to repair tissue at the site of implantation. As the patient's cells populate the matrix, they lay down their own collagen, which matures over time to form a functional tissue repair. The implanted ECM material is gradually replaced and resorbed by the body as the patient's tissue is remodeled.

"We are honored to be presented with this Award, as the recognition further validates the increasing interest and acceptance that our ECM Technology(TM) continues to receive within the clinical community," commented Beecher Lewis, President and Chief Operating Officer of CorMatrix Cardiovascular.

The use of extracellular matrix technology in non-cardiovascular applications has established a significant foothold in soft tissue repair, wound management and orthopedic applications. Since the launch of CorMatrix's ECM for Pericardial Closure, the technology has been used at more than 220 hospitals across the U.S. and has been implanted in more than 9,000 cardiac procedures.

About CorMatrix ECM Technology(TM)

CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications. The company currently has U.S. clearance and European approval with a CE Mark to market its ECM Technology as an implant for pericardial closure, clearance in the U.S. for cardiac tissue repair, and is conducting preclinical studies on a number of cardiovascular applications including an emulsified, injectible form of its ECM Technology as a potential treatment for heart failure.

About CorMatrix Cardiovascular, Inc.

CorMatrix Cardiovascular, a privately held company based in Atlanta, Georgia, is dedicated to developing and delivering innovative biomaterial devices that harness the body's own innate ability to regenerate damaged heart tissue. For more information visit http://www.cormatrix.com.


'/>"/>
SOURCE CorMatrix Cardiovascular Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aposense Receives Frost & Sullivan Technology Innovation of the Year Award
2. Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award
3. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
4. Frost & Sullivan Acknowledges ISTO Technologies Role in Developing Advanced Biologic Products for Bone Healing
5. Small Animal Imaging Market: Biospace Lab Wins Frost & Sullivan Accolade for Its Successful Product Line Strategy
6. Celsis Receives Frost & Sullivan 2008 Best Practices Award
7. ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems
8. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
9. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
10. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
11. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):